Carbamylated low-density lipoprotein induces endothelial dysfunction

European Heart Journal

Volumn 35, Issue 43, 2014, Pages 3021-3032

  Speer, Thimoteus ^a,b,c   Owala, Frederick O ^a,b   Holy, Erik W ^a,b   Zewinger, Stephen ^c   Frenzel, Felix L ^c   Stähli, Barbara E ^a,b   Razavi, Marjan ^b   Triem, Sarah ^c   Cvija, Hrvoje ^c   Rohrer, Lucia ^d   Seiler, Sarah ^c   Heine, Gunnar H ^c   Jankowski, Vera ^e   Jankowski, Joachim ^e   Camici, Giovanni G ^b   Akhmedov, Alexander ^b   Fliser, Danilo ^c   Lüscher, Thomas F ^a,b   Tanner, Felix C ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carbamylation; Endothelial function; Lipoprotein; Nitric oxide; Reactive oxygen species

Indexed keywords

ACETYLCHOLINE; CALCIMYCIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; CARBAMYL-LDL; CATION; DIPHENYLIODONIUM SALT; ENZYME INHIBITOR; OLR1 PROTEIN, MOUSE; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CARBAMOYLATION; CHRONIC KIDNEY DISEASE; ELECTRON SPIN RESONANCE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; FOLLOW UP; HUMAN; LIPID PEROXIDATION; MOUSE; NONHUMAN; ANALYSIS OF VARIANCE; ANIMAL; AORTA; C57BL MOUSE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; IN VITRO STUDY; METABOLISM; NORMAL HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANALYSIS OF VARIANCE; ANIMALS; AORTA; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HEALTHY VOLUNTEERS; HUMANS; IN VITRO TECHNIQUES; LIPOPROTEINS, LDL; MICE, INBRED C57BL; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE TYPE III; ONIUM COMPOUNDS; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; SCAVENGER RECEPTORS, CLASS E; VASODILATION; VASODILATOR AGENTS;

EID: 84904632796     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu111     Document Type: Article

References (37)

1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: Final Data for 2006. National vital statistics reports. Hyattsville, MD: National Center for Healthy Statistics; 2009.
2. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, WenCP, Nelson RG. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012;380:1662-1673.
3. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380: 807-814.
4. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-455.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-1389.
8. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-1369.
9. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
10. Libby P, Ridker PM, MaseriA. Inflammation and atherosclerosis. Circulation 2002;105: 1135-1143.
11. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992;70:1191-1197.
12. Tanner FC, Noll G, Boulanger CM, Luscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation 1991;83:2012-2020.
13. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002;22:1649-1654.
14. Meisinger C, Baumert J, Khuseyinova N, Loewel H, KoenigW. Plasma oxidized lowdensity lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005; 112:651-657.
15. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R. Circulating oxidized low density lipoprotein levels.Abiochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2243-2247.
16. Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005;68:173-178.
17. Koeth RA, Kalantar-Zadeh K, Wang Z, Fu X, Tang WH, Hazen SL. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol 2013;24:853-861.
18. KrausLM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001;78:S102-S107.
19. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1176-1184.
20. Apostolov EO, Ray D, Savenka AV, Shah SV, Basnakian AG. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J AmSoc Nephrol 2010;21:1852-1857.
21. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, Kania G, Zewinger S, Akhmedov A, Shi Y, Martin T, Perisa D, Winnik S, Müller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann FH, Landmesser U. Abnormal highdensity lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity 2013;38:754-768.
22. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111:1201-1209.
23. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-605.
24. ForstermannU, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708-1714.
25. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010;468:1115-1118.
26. Apostolov EO, Shah SV, Ray D, Basnakian AG. Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol 2009;29:1622-1630.
27. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, Sawamura T. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000;275:12633-12638.
28. Dandapat A, Hu C, Sun L, Mehta JL. Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler Thromb Vasc Biol 2007;27:2435-2442.
29. Berg AH, Drechsler C, Wenger J, Buccafusca R, Hod T, Kalim S, Ramma W, Parikh SM, Steen H, Friedman DJ, Danziger J, Wanner C, Thadhani R, Karumanchi SA. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 2013;5:175-129.
30. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424.
31. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
32. Mineo C, Deguchi H, Griffin JH, ShaulPW. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98:1352-1364.
33. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006;185:219-226.
34. Hein TW, Liao JC, Kuo L. oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles. Am J Physiol Heart Circul Physiol 2000; 278:H175-H183.
35. McNeill KL, Fontana L, Russell-Jones DL, Rajman I, Ritter JM, Chowienczyk PJ. Inhibitory effects of low-density lipoproteins from men with type II diabetes on endothelium-dependent relaxation. J Am Coll Cardiol 2000;35:1622-1627.
36. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999;99: 3110-3117.
37. Carracedo J, Merino A, Briceno C, Soriano S, Buendia P, Calleros L, Rodriguez M, Martin-Malo A, Aljama P, Ramirez R. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J 2011;25:1314-1322.